Literature DB >> 3722826

Separation of tumor-infiltrating lymphocytes from tumor cells in human solid tumors. A comparison between velocity sedimentation and discontinuous density gradients.

T L Whiteside, S Miescher, H R MacDonald, V Von Fliedner.   

Abstract

The separation of viable tumor-infiltrating lymphocytes (TIL) from surgical biopsies of human solid tumors was achieved by velocity sedimentation at unit gravity or by discontinuous density gradients. The two methods were adapted to small volumes and cell numbers not exceeding 1 X 10(8). The recovery, purity and composition of the TIL-enriched fractions were comparable in the two methods. Density gradients were more rapid, simpler and more practical for preparation under sterile conditions of TIL from clinical material than velocity sedimentation. Lymphocytes in the TIL-enriched fractions obtained by either of the methods were poorly responsive to mitogens. This poor responsiveness is a characteristic of the human TIL and seems to be related to effects exerted by tumor cells.

Entities:  

Mesh:

Year:  1986        PMID: 3722826     DOI: 10.1016/0022-1759(86)90079-7

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  22 in total

1.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

2.  Antibody response to human papillomavirus vaccination and natural exposure in individuals with Fanconi Anemia.

Authors:  Parinda A Mehta; Sharon Sauter; Xue Zhang; Stella M Davies; Suzanne I Wells; Kasiani C Myers; Gitika Panicker; Elizabeth R Unger; Melinda Butsch Kovacic
Journal:  Vaccine       Date:  2017-10-16       Impact factor: 3.641

3.  Dendritic cell-based autologous tumor vaccines for head and neck squamous cell carcinoma.

Authors:  Theresa L Whiteside; Robert L Ferris; Miroslaw Szczepanski; Mitchell Tublin; Joseph Kiss; Rita Johnson; Jonas T Johnson
Journal:  Head Neck       Date:  2015-07-15       Impact factor: 3.147

4.  High expression of adhesion molecules/activation markers with little interleukin-2, interferon gamma, and tumor necrosis factor beta gene activation in fresh tumor-infiltrating lymphocytes from lung adenocarcinoma.

Authors:  E Roussel; M C Gingras; E A Grimm; J A Roth
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

5.  Effects of cytokines on in vitro growth of tumor-infiltrating lymphocytes obtained from human primary and metastatic liver tumors.

Authors:  Y Shimizu; S Iwatsuki; R B Herberman; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  T cell killing of human colon carcinomas by monoclonal-antibody-targeted superantigens.

Authors:  P A Lando; M Dohlsten; G Hedlund; E Akerblom; T Kalland
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

Review 7.  Human autologous tumor-specific T cells in malignant melanoma.

Authors:  C D Platsoucas
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

8.  Functional analysis of TCR gamma delta+ T cells in tumour-infiltrating lymphocytes (TIL) of human pancreatic cancer.

Authors:  J Kitayama; Y Atomi; H Nagawa; A Kuroda; T Mutoh; M Minami; T Juji
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

9.  Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes.

Authors:  M J Maeurer; D M Martin; C Castelli; E Elder; G Leder; W J Storkus; M T Lotze
Journal:  Cancer Immunol Immunother       Date:  1995-08       Impact factor: 6.968

10.  CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues.

Authors:  Sadna Budhu; John D Loike; Ashley Pandolfi; Soo Han; Geoffrey Catalano; Andrei Constantinescu; Raphael Clynes; Samuel C Silverstein
Journal:  J Exp Med       Date:  2010-01-11       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.